I am 42. Which biologic is best for me to start?

Question

Hello doctor,

I am a 42-year-old woman who was recently diagnosed with seropositive rheumatoid arthritis. I experience morning stiffness in my wrists and knees that lasts for more than one hour, and my C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are elevated.

I have been taking Methotrexate (disease-modifying antirheumatic drug – DMARD) for approximately four months, but the joint pain and swelling continue to persist.

My doctor has mentioned biologic medications such as Etanercept or Adalimumab as possible options.

Please tell me,

How is the decision made regarding which biologic to begin?
What are the long-term risks and benefits of these treatments, particularly in relation to infections or liver health?

Kindly help.

Answer 1

Hello,

Welcome to icliniq.com.

I have read your query and can understand your concern.

Since you have seropositive rheumatoid arthritis with persistent joint inflammation despite taking Methotrexate (disease-modifying antirheumatic drug – DMARD) for several months, considering biologic therapy is appropriate.

The choice between agents such as Etanercept (tumor necrosis factor inhibitor – TNF inhibitor) or Adalimumab (tumor necrosis factor inhibitor – TNF inhibitor) often depends on several factors, including your disease activity, prior treatment response, coexisting medical conditions, cost and insurance coverage, and personal preference regarding the mode and frequency of injections.

Both of these drugs belong to the class of tumor necrosis factor inhibitors. They are effective in reducing inflammation, preventing joint damage, and improving physical function in patients who do not achieve adequate control with Methotrexate alone. They are usually combined with Methotrexate for better long-term outcomes.

The main long-term benefits of these therapies include sustained reduction in joint pain and swelling, improved quality of life, and protection against progressive joint deformities.

However, the risks primarily involve suppression of the immune system, which can increase susceptibility to infections, particularly tuberculosis, hepatitis B reactivation, and opportunistic infections. Therefore, screening before starting treatment is essential.

Your doctor will usually recommend appropriate vaccinations before initiating therapy and will continue to monitor your blood work and clinical response closely.

Ultimately, the decision is made through shared discussion, balancing the potential for improved disease control with the safety considerations that are most relevant to your health profile.

I hope this helps.

Thank you.